/ACRV
ACRV Stock - Acrivon Therapeutics, Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$2.16-4.42%
$0.10 (-4.42%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.69
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.49
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+952.3%upside
Target: $22.73
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ACRV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.14 – $2.18
TARGET (TP)$22.73
STOP LOSS$1.99
RISK/REWARD1:121.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.77
52W High$8.00
52W Low$1.05
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-1,006,000 | $-536,000 | N/A | N/A | $-13,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-89,199,000 | $-67,237,000 | $-32,657,000 | $-16,184,000 | $-3,168,000 |
| Net Income | $-80,556,000 | $-60,388,000 | $-31,167,000 | $-16,243,000 | $-5,306,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.10 | $-2.74 | $-1.42 | $-1.26 | $-0.41 |
Company Overview
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
91%
Hold / Neutral
1
9%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
10 Bullish1 Neutral/Bearish
Price Targets
$19
Average Target
↑ 761.1% Upside
Now
$6
Low
$19
Average
$25
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 5th 2025 | Piper Sandler | Resumed | Overweight | $6 |
| January 31st 2025 | KeyBanc Capital Markets | Initiation | Overweight | - |
| September 16th 2024 | Ladenburg Thalmann | Upgrade | Buy | $16 |
| April 29th 2024 | Ladenburg Thalmann | Downgrade | Neutral | - |
| March 1st 2024 | JMP Securities | Initiation | Mkt Outperform | $14 |
| December 15th 2023 | Jefferies | Resumed | Buy | $12← $17 |
| October 5th 2023 | Maxim Group | Initiation | Buy | - |
| June 2nd 2023 | Oppenheimer | Initiation | Outperform | $25 |
| May 8th 2023 | BMO Capital Markets | Initiation | Outperform | $25 |
| April 27th 2023 | Ladenburg Thalmann | Initiation | Buy | $22 |
| April 20th 2023 | H.C. Wainwright | Initiation | Buy | $24 |
| December 12th 2022 | Jefferies | Initiation | Buy | $17 |
| December 12th 2022 | Piper Sandler | Initiation | Overweight | $25 |
| December 12th 2022 | Cowen | Initiation | Outperform | - |
Earnings History & Surprises
ACRVBeat Rate
85%
Last 13 quarters
Avg Surprise
+13.5%
EPS vs Estimate
Beats / Misses
11/2
Last 12 quarters
Latest EPS
$-0.47
Q4 2025
EPS Surprise History
Q1 24
-19.4%
$-0.86vs$-0.72
Q2 24
+18.0%
$-0.73vs$-0.89
Q3 24
+11.9%
$-0.52vs$-0.59
Q4 24
-5.4%
$-0.59vs$-0.56
Q1 25
+13.0%
$-0.60vs$-0.69
Q2 25
+10.5%
$-0.51vs$-0.57
Q3 25
+3.5%
$-0.55vs$-0.57
Q4 25
+17.5%
$-0.47vs$-0.57
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.49 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.57 | $-0.47 | +17.5% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.57 | $-0.55 | +3.5% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.57 | $-0.51 | +10.5% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.69 | $-0.60 | +13.0% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.56 | $-0.59 | -5.4% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.59 | $-0.52 | +11.9% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.89 | $-0.73 | +18.0% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-0.72 | $-0.86 | -19.4% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.72 | $-0.66 | +8.3% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-0.68 | $-0.63 | +7.4% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.60 | $-0.58 | +3.3% | ✓ BEAT |
Q1 2023 | Mar 28, 2023 | $-1.09 | $-0.80 | +26.6% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-2.44 | $-0.47 | +80.8% | ✓ BEAT |
Q3 2022 | Aug 14, 2022 | — | $-0.44 | — | — |
Q2 2022 | May 15, 2022 | — | $-0.56 | — | — |
Q1 2022 | Feb 14, 2022 | — | $-0.17 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.34 | — | — |
Latest News
Acrivon Therapeutics Said It Will Be Providing ACR-368 and ACR-2316 Clinical Data And Other Updates In January 2026
➖ NeutralBenzinga•Dec 17, 2025, 12:35 PM
HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target
📈 PositiveBenzinga•Nov 25, 2025, 11:45 AM
Acrivon Therapeutics Q3 EPS $(0.47) Beats $(0.61) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:13 PM
Acrivon Therapeutics To Deliver Three Presentations At The AACR-NCI-EORTC Highlighting Advances From Its Proprietary Generative Phosphoproteomics AP3 Platform For Developing Precision Medicines
📈 PositiveBenzinga•Oct 22, 2025, 08:29 PM
Acrivon Posts Narrower Loss in Q2
📈 PositiveThe Motley Fool•Aug 13, 2025, 10:07 PM
Frequently Asked Questions about ACRV
What is ACRV's current stock price?
Acrivon Therapeutics, Inc. Common Stock (ACRV) is currently trading at $2.16 per share. The stock has moved -4.42% today.
What is the analyst price target for ACRV?
The average analyst price target for ACRV is $22.73, based on 1 analyst.
What sector is Acrivon Therapeutics, Inc. Common Stock in?
Acrivon Therapeutics, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ACRV's market cap?
Acrivon Therapeutics, Inc. Common Stock has a market capitalization of $0.07 billion, making it a small-cap company.
Does ACRV pay dividends?
No, Acrivon Therapeutics, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATYR
aTyr Pharma, Inc.
$0.75
Mkt Cap: $0.1B
BMEA
Biomea Fusion, Inc.
$1.40
Mkt Cap: $0.1B
CBUS
Cibus, Inc.
$1.71
Mkt Cap: $0.1B
IMUX
Immunic, Inc.
$0.57
Mkt Cap: $0.1B
PMVP
PMV Pharmaceuticals, Inc.
$1.24
Mkt Cap: $0.1B
RLMD
Relmada Therapeutics, Inc.
$4.35
Mkt Cap: $0.3B
RPTX
Repare Therapeutics Inc.
$2.14
Mkt Cap: $0.1B
TCRX
TScan Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
UNCY
Unicycive Therapeutics, Inc.
$5.56
Mkt Cap: $0.1B
VXRT
Vaxart, Inc.
$0.35
Mkt Cap: $0.1B
Explore stocks similar to ACRV for comparison